Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 12/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | HAO1 | Q9UJM8 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | PTPRC | P08575 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1657080 | 0.84 | GRM5 (0.64) | GRM5 | |
| SCHEMBL1657915 | 0.84 | GRM5 (0.49) | GRM5 | |
| SCHEMBL1658000 | 0.84 | GRM5 (0.49) | GRM5NPC1RAB9ASMN1; SMN2PTGES | |
| SCHEMBL1657235 | 0.83 | GRM5 (0.50) | GRM5PTGDR2HAO1NPC1RAB9A | |
| SCHEMBL1657703 | 0.82 | GRM5 (0.73) | GRM5NPC1RAB9A | |
| SCHEMBL1657766 | 0.82 | GRM5 (0.52) | GRM5CYP2C9PTGDR2NPC1RAB9A | |
| SCHEMBL1656777 | 0.81 | GRM5 (0.75) | GRM5NPC1RAB9A | |
| SCHEMBL1657349 | 0.80 | L3MBTL1 (0.51) | GRM5NPC1RAB9A | |
| SCHEMBL1657004 | 0.80 | GRM5 (0.42) | GRM5CYP2C9PTGDR2NPC1POLB | |
| SCHEMBL1658423 | 0.79 | GRM5 (0.59) | GRM5NPC1POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231321-A1 | 2-SUBSTITUTED-ETHYNYLTHIAZOLE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2013-09-05 | — | — | US | disclosed |
| US-8440837-B2 | 2-substituted-ethynylthiazole derivatives and uses of same | H. LUNDBECK A/S (DK) | 2013-05-14 | — | — | US | disclosed |
| EP-2490541-A1 | 2-SUBSTITUTED-ETHYNYLTHIAZOLE DERIVATIVES AND USES OF SAME | H. Lundbeck A/S (DK) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011050063-A1 | 2-SUBSTITUTED-ETHYNYLTHIAZOLE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2011-04-28 | — | — | WO | disclosed |
| US-20110092475-A1 | 2-SUBSTITUTED-ETHYNYLTHIAZOLE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231321-A1 | 2-SUBSTITUTED-ETHYNYLTHIAZOLE DERIVATIVES AND USES OF SAME | SULT1E1, SULT2A1, SULT1A1 | GRM5 3131/4885CYP2C9 43/4885PTGDR2 474/4885 |
| US-20110092475-A1 | 2-SUBSTITUTED-ETHYNYLTHIAZOLE DERIVATIVES AND USES OF SAME | SULT1E1, SULT2A1, SULT1A1 | GRM5 3131/4885CYP2C9 43/4885PTGDR2 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.